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a b s t r a c t
The γ34.5 gene of herpes simplex virus (HSV) 2 encodes ICP34.5, which enhances HSV-2 neurovirulence
by an unknown mechanism. We found that an HSV-2 γ34.5-null mutant (γ34.5/) replicated less
robustly than its rescue virus (γ34.5R) in wild-type mouse embryo ﬁbroblasts (MEFs), and in cells
primed with IFNβ. Increased eIF2α phosphorylation correlated with γ34.5/ attenuation. However,
γ34.5/ achieved titers equivalent to γ34.5R in MEFs lacking the type I IFN receptor (IFNα/βR/) or
lacking protein kinase R. γ34.5/ also replicated poorly in the vaginal mucosa of wild-type mice,
caused little genital inﬂammation, and spread to the nervous system at lower levels compared to γ34.5R.
In IFNα/βR/ mice, however, γ34.5/ regained the capacity to replicate and cause disease equivalent to
γ34.5R after intravaginal infection or direct inoculation into the central nervous system. Thus, the capacity
of HSV-2 ICP34.5 to interdict the type I IFN response in vivo largely determines its neurovirulence.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Herpes simplex viruses (HSVs) are neurotropic, and after initial
infection of an epithelial surface virus spreads to the cell body of
sensory neurons innervating the epithelium. HSV-1 typically infects
oral or corneal epithelia whereas HSV-2 causes most genital
ulcerative disease. A hallmark of HSV infection is maintenance of
the viral genome in a repressed, latent state in sensory nerve
ganglia. Reactivation of the viral genome to a state of productive
replication results in asymptomatic viral shedding from the epithe-
lium or recurrent ulcerative disease. The capacity to enter latency
prevents HSV from being cleared and this results in a high global
burden of infection; an estimated 500 million people are infected
with HSV-2 (Looker et al., 2008). When virus ascends from
peripheral neurons to the CNS, replication can lead to relatively
rare but severe neurological disease. This is particularly evident in
immunocompromised patients (Mommeja-Marin et al., 2003;
Jancel and Penzak, 2009) and in infants infected during birth
(Kimberlin and Whitley, 2005; Pinninti and Kimberlin, 2013).
The highly related genomes of HSV-1 and HSV-2 contain two
copies of the γ34.5 gene located in the inverted repeats (McGeoch
et al., 1991). The γ34.5 gene product, infected cell protein (ICP)
34.5, contributes signiﬁcantly to HSV pathogenesis and also to
neurovirulence, as deﬁned by attenuation after intracranial (i.c.)
inoculation into mice of virus containing a deletion or mutation in
γ34.5 (Taha et al., 1989a, 1989b; Chou et al., 1990; Bolovan et al.,
1994; Valyi-Nagy et al., 1994). The role of γ34.5 in HSV-1
pathogenesis has been linked to its capacity to counteract the
type I IFN response. For example, following ocular infection an
HSV-1 γ34.5-null mutant replicates to a greater extent in the
cornea and trigeminal ganglia of mice that lack the common type I
IFN receptor (IFNα/βR /) than it does in wild-type (wt) mice
(Leib et al., 1999). An HSV-1 γ34.5-null mutant also regains the
virulence of wt virus after i.c. inoculation into IFNα/βR / mice
(Leib et al., 2000).
The mechanisms by which HSV-1 ICP34.5 counteracts the
type I IFN response have been well-characterized. HSV-1 ICP34.5
binds four cellular proteins: Beclin-1 (Orvedahl et al., 2007) and
tank-binding kinase 1 (TBK1) (Verpooten et al., 2009) via its
N-terminal domain, and protein phosphatase 1α (PP1α) (He et al.,
1998; Cheng et al., 2001b) and eukaryotic translation initiation
factor 2α (eIF2α) (Li et al., 2011) via its C-terminal domain. HSV-1
ICP34.5 binding of TBK1 inhibits the induction of IFNβ in transfec-
tion experiments (Verpooten et al., 2009; Ma et al., 2012), and a
virus with an N-terminal deletion that includes the TBK1 binding
domain replicates very poorly in the cornea and does not reach the
nervous system (Ma et al., 2012). PP1α dephosphorylates eIF2α
when binding by ICP34.5 brings them into close proximity (He et al.,
1998; Li et al., 2011), thus counteracting IFN-stimulated protein
kinase R (PKR) activity to prevent translational shutoff (He et al.,
1997, 1998). Amino acid residues within the PP1α binding domain
are critical determinants of HSV-1 IFN resistance (Cheng et al.,
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2001a), and a virus with mutation of these residues similarly is
highly attenuated when inoculated onto the cornea (Verpooten
et al., 2009). Lastly, HSV-1 ICP34.5 binds and sequesters the pro-
autophagic mediator Beclin-1 to prevent the formation of autopha-
gosomes (Orvedahl et al., 2007) in a process also dependent on
PKR-mediated phosphorylation of eIF2α (Talloczy et al., 2002). The
binding of HSV-1 ICP34.5 to Beclin-1 (Orvedahl et al., 2007), and
antagonism of the PKR signaling pathway (Leib et al., 2000;
Orvedahl et al., 2007) contribute to neurovirulence.
An HSV-2 mutant with deletions of γ34.5 and a large amount of
upstream sequence was used to identify HSV-2 ICP34.5 as a major
neurovirulence factor (Taha et al., 1989a, 1989b). The severity of
HSV-2 infections also depends in part on virus control of the type I
IFN response (Murphy et al., 2003; Gill et al., 2006). Some evidence
suggests the analogous eIF2α and PP1α binding domains of HSV-2
ICP34.5 are functional (Wylie et al., 2009; Tang et al., 2013), and
indeed, strong sequence conservation with HSV-1 ICP34.5 in the
C-terminal domain supports this contention. However, the precise
role of HSV-2 ICP34.5 in neurovirulence, the effect of HSV-2
ICP34.5 on the type I IFN response, and whether control of the
IFN response by ICP34.5 contributes to HSV-2 neurovirulence have
not been established. Therefore, we investigated whether HSV-2
ICP34.5 counteracts the type I IFN response, and the potential
impact of IFN resistance on ICP34.5's role in HSV-2 neurovirulence.
Results
Construction of HSV-2 γ34.5-null mutant and rescue viruses
The HSV-2 isolate used to identify γ34.5 as a neurovirulence
factor (variant JH2604) contains a lesion that deleted the γ34.5
open reading frame (ORF) and more than 500 bp of the 50
untranslated region (Taha et al., 1989a, 1989b). In order to examine
the precise function of γ34.5 in HSV-2 replication and virulence,
we created a γ34.5 null mutant (γ34.5/) in the HSV-2 strain 333
background (333 wt) (Fig. 1A) which speciﬁcally targets γ34.5 to
prevent ICP34.5 expression while preserving other features of this
genomic region (Tang et al., 2008, 2009; Jurak et al., 2010). Two
mutations were made in the γ34.5 ORF: a stop codon was inserted
at amino acid 13, and a M35A mutation was introduced to alter the
only internal methionine (Fig. 1A). A plasmid expressing the
mutated γ34.5 ORF was co-transfected with full-length wt viral
DNA and isolated plaques were screened by PCR. A recombinant
virus in which of both copies of γ34.5 had been replaced was
plaque-picked to homogeneity to generate γ34.5 / . To ensure
that only the intended sites were altered in γ34.5 / , it was
rescued back to the wt sequence by homologous recombination
and the resultant virus was termed γ34.5R. Western blot of Vero
cell lysates using rabbit antiserum revealed two forms of HSV-2
ICP34.5 in lysates prepared from γ34.5R- and 333 wt-infected cells
(Fig. 1B), consistent with previous observations (Tang et al., 2008;
Wylie et al., 2009; Korom et al., 2014). ICP34.5 was not detected in
lysates from uninfected or γ34.5 /-infected samples (Fig. 1B).
To examine whether the mutations in the γ34.5 ORF altered
virus replication, growth over time post-infection was determined
in Vero cells infected at low multiplicity of infection (MOI). Vero
cells are highly permissive to HSV infection because of deletions in
the alpha- (α) and beta1- (β1) IFN genes (Emeny and Morgan,
1979; Mosca and Pitha, 1986). Infection with γ34.5 / , γ34.5R,
and 333 wt viruses at MOI of 0.01 pfu/cell yielded overlapping
growth curves (Fig. 1C), demonstrating γ34.5 / has no intrinsic
replication defect. Infection at high MOI (10 pfu/cell) also resulted
in similar titers over time (data not shown). To rigorously verify
that γ34.5R was rescued to 333 wt phenotype, groups of 129 mice
were infected intravaginally (i.vag.) with γ34.5R or 333 wt.
Replication in the vaginal mucosa over time post-infection was
highly similar between the two viruses (Fig. 1D), as was viral titer
in the CNS at 6 d post-infection (d p.i.) (Fig. 1E). We therefore
compared γ34.5 / with γ34.5R in subsequent experiments
because γ34.5R phenotypically and genotypically rescued
γ34.5 / back to 333 wt.
The type I IFN response attenuates HSV-2 γ34.5 / replication in
MEFs
To determine whether HSV-2 ICP34.5 contributes to type I IFN
resistance, we ﬁrst asked whether replication of HSV-2 lacking
ICP34.5 is attenuated in a type I IFN sufﬁcient environment. MEFs
isolated from 129 wt mice and IFNα/βR/ mice were infected at
low MOI with either HSV-1 Δγ34.5 and its rescue virus, Δγ34.5R,
as positive control for IFNα/β sensitivity, or with HSV-2 γ34.5 /
and γ34.5R. In wt MEFs, Δγ34.5 replicated at much lower levels
than Δγ34.5R from 24 to 48 h p.i. (Fig. 2A). The HSV-2 mutant
followed the same pattern in that γ34.5 / replication was
signiﬁcantly reduced compared with γ34.5R from 24 to 48 h p.i.
(Fig. 2B). In MEFs unable to signal through the type I IFN receptor,
HSV-1 Δγ34.5 replication recovered to within 40-fold of Δγ34.5R
(Fig. 2C), indicating a role for type I IFN in its attenuation.
Strikingly, replication of the HSV-2 γ34.5 / mutant fully recov-
ered to the level of γ34.5R in IFNα/βR / MEFs (Fig. 2D). The HSV-
2 γ34.5 / mutant also replicated like γ34.5R in both wt and
IFNα/βR / MEFs after infection at high MOI (data not shown),
where autocrine production of type I IFN is insufﬁcient to inhibit
ongoing HSV infection (Duerst and Morrison, 2004).
Effect of HSV-2 ICP34.5 on IFNβ priming
High titers of HSV-2 γ34.5 / in IFNα/βR / MEFs (Fig. 2)
suggested HSV-2 ICP34.5 participates in inhibition of the type I IFN
response. To determine whether HSV-2 γ34.5 can overcome
priming by type I IFN, wt MEFs were pretreated with 0 or
100 IU/ml of IFNβ and then infected with HSV-2 γ34.5/ or
γ34.5R at MOI of 10. Both viruses replicated to high titers by 24 h
p.i. in untreated MEFs (Fig. 3A). In MEFs pretreated with IFNβ,
γ34.5R still replicated efﬁciently but replication of γ34.5 / was
signiﬁcantly reduced. We also pretreated primary human foreskin
ﬁbroblasts with 0 or 100 IU/ml of IFNβ, and again γ34.5R repli-
cated efﬁciently under both conditions (Fig. 3B), but γ34.5 /
replication was attenuated. Similarly, HSV-1 Δγ34.5 replication
was suppressed to a greater extent than Δγ34.5R in IFN-
pretreated cells (data not shown). Levels of suppression in HFFs
pretreated with 1000 IU/ml of IFNβ were similar to pretreatment
with 100 IU of IFNβ (data not shown).
Type I IFN signaling triggers PKR induction and subsequent
infection activates PKR to phosphorylate eIF2α, causing transla-
tional arrest. eIF2α phosphorylation positively correlates with
attenuation of an HSV-2 mutant expressing reduced amounts of
ICP34.5 (Wylie et al., 2009), and HSV-2 γ34.5 transfection alle-
viates eIF2α phosphorylation in cells infected with γ34.5-deﬁcient
HSV-1 (Tang et al., 2013). We therefore used γ34.5/ to deter-
mine whether HSV-2 ICP34.5 opposes PKR-mediated eIF2α phos-
phorylation during HSV-2 infection. As expected, HSV-1 Δγ34.5R
and HSV-2 γ34.5R suppressed phosphorylated eIF2α below the
level in mock-infected MEFs (Fig. 3C). In contrast, more phos-
phorylated eIF2α accumulated in MEFs infected with Δγ34.5 or
γ34.5 / compared to mock-infected cells and cells infected with
the wild-type viruses (Fig. 3C). γ34.5 / infection of HFFs yielded
similar results (data not shown). These observations provide
evidence that HSV-2 γ34.5 / cannot counteract the PKR path-
way. Consistent with this interpretation, γ34.5/ replicated as
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well as γ34.5R in PKR / MEFs, even when the cells had been
pretreated with IFNβ (Fig. 3D).
Replication and disease induced by γ34.5 / after vaginal infection of
mice
To determine whether HSV-2 ICP34.5 also counteracts the type
I IFN response in vivo, 129 wt and IFNα/βR/ mice were infected
i.vag. with HSV-2 γ34.5 / or γ34.5R. In wt mice, γ34.5 / and
γ34.5R replicated to similar extents in the vaginal mucosa through
the ﬁrst 3 d p.i. (Fig. 4A). γ34.5 / titers rapidly dropped there-
after, whereas replication of γ34.5R continued unabated. Genital
inﬂammation progressed quickly to lesion formation by 6 d p.i. in
many wt mice infected with γ34.5R (Fig. 4B). In contrast, γ34.5 /
infection caused signiﬁcantly less inﬂammation and no lesions
were observed. High titers of γ34.5R were found in the spinal cord
and brainstem at 6 d p.i. (Fig. 4C). Signiﬁcantly lower titers of
γ34.5 / were recovered from the spinal cord, and virus was
below the level of detection in the brain and brainstem (Fig. 4C).
Thus by all measures, HSV-2 γ34.5 / infection in wt mice was
attenuated compared with γ34.5R. In contrast, γ34.5 / and
γ34.5R both achieved high titers in the vaginal mucosa of IFNα/
βR / mice by 2 d p.i. and both viruses continued to replicate
efﬁciently through 5 d p.i. (Fig. 4D). Severe genital inﬂammation
was observed in IFNα/βR/ mice infected with either γ34.5 /
or γ34.5R, and lesions developed by day 6 (Fig. 4E). In the spinal
cords and brainstems of IFNα/βR / mice, γ34.5 / and γ34.5R
replicated to comparable titers, and titers in the brain were not
signiﬁcantly different (Fig. 3F). Thus, the attenuation of γ34.5 /
replication and capacity to cause disease relative to γ34.5R was
abolished in IFNα/βR/ mice.
Limited genital disease and low CNS titers in wt mice on day
6 after γ34.5 / infection (Fig. 4A) could possibly have been due
to delayed kinetics of viral dissemination from the vaginal mucosa.
To determine whether γ34.5 / infection eventually became as
severe as γ34.5R, mice were infected i.vag. with γ34.5 / or
γ34.5R and monitored daily for morbidity. All wt mice infected
with γ34.5R succumbed to disease by 9 d p.i., while 40% of wt mice
Fig. 1. Construction of HSV-2 γ34.5 null mutant and rescue viruses. (A) The genomic structure of HSV-2 γ34.5 (line 1) and γ34.5 mutagenesis scheme. An expanded view of
the long inverted repeat (line 2) shows the location and orientation of transcripts encoding ICP0 and ICP34.5, and miRs within the γ34.5 locus. Line 3 shows the γ34.5 ORF.
Line 4 shows mutagenesis to insert a stop codon at amino acid 13 and an M35A mutation in the γ34.5 ORF. (B) Western blot of HSV-2 ICP34.5. Vero cells were mock infected
or infected at MOI of 5 with HSV-2 333 wt, γ34.5/ , or γ34.5R and harvested 12 h p.i. The blot was probed with rabbit polyclonal antiserum to ICP34.5 or to total eIF2α.
(C) Replication of the viruses after low MOI (0.01 pfu/cell) infection of Vero cells. Cultures were collected at the indicated time points and viral titers were determined by
plaque assay. Data represent the geometric mean7SEM of triplicate cultures from one representative experiment out of two performed. (D) Titer of virus shed from the
vaginal mucosa of wt mice infected i.vag. with 1104 pfu/mouse of the indicated virus. (E) Viral titer in nervous system tissues, determined 6 d p.i. Data in D and E represent
the geometric meanþSEM of a total of 7 to 8 mice per group compiled from two independent experiments. Dotted lines in panels C–E represent limit of detection in the
plaque assay, which is higher for brain due to disruptive effects of the dense tissue homogenate on the plaque assay cell monolayer at high concentration.
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infected with γ34.5 / survived the infection (Fig. 5A). In contrast,
all IFNα/βR / mice infected with either HSV-2 γ34.5/ or
γ34.5R died by 8 d p.i. (Fig. 5B).
γ34.5 / replication after intracranial inoculation
Limited replication of γ34.5 / in the CNS of wt mice after i.
vag. infection could have resulted from reduced dissemination of
virus into the CNS from the vaginal mucosa rather than relative
inability to replicate in neural tissues. To directly assess the
capacity of γ34.5 / to replicate in the CNS, wt and IFNα/βR /
mice were infected i.c. with γ34.5 /and γ34.5R. 24 h p.i., γ34.5R
titers in the brain had increased 45-fold over the inoculum dose
(Fig. 6A). However, the amount of γ34.5/ virus recovered was
lower than the inoculum, indicating γ34.5/ did not replicate
efﬁciently in the brain. Correspondingly, wt mice infected i.c. with
γ34.5R precipitously succumbed to infection, but survival of mice
infected with γ34.5 / was much more protracted and 30% of the
mice ultimately recovered (Fig. 6B). In IFNα/βR / mice, high
titers of both γ34.5 / and γ34.5R were recovered 24 h p.i.
(Fig. 6C). To ensure that recovery of mutant virus replication in
the absence of a type I IFN response was not a general phenom-
enon, we also tested an HSV-2 thymidine kinase (TK) mutant,
ΔTK . Like γ34.5 / , ΔTK replicated inefﬁciently after direct
injection into the CNS of wt mice (Fig. 6A). However, in contrast to
γ34.5 / , replication ofΔTK did not recover in IFNα/βR/ mice
(Fig. 6C). All IFNα/βR/ mice died by 5 d p.i. whether they had
been infected with γ34.5 / or γ34.5R (Fig. 6D). Therefore,
ICP34.5 speciﬁcally controls HSV-2 neurovirulence through its
capacity to counteract the type I IFN response.
Discussion
HSV-2 ICP34.5 was implicated long ago as an important
neurovirulence factor. An HSV-2 with a targeted mutation that
disrupts only ICP34.5 expression is attenuated for replication
relative to its rescue virus in wt MEFs and mice, but recovers to
the level of γ34.5R in IFNα/βR/ MEFs and mice. Similarly,
disease progression after peripheral inoculation of γ34.5 /
resembles γ34.5R in IFNα/βR / but not wt mice. These observa-
tions indicate ICP34.5 contributes to HSV-2 pathogenesis in vivo
through a mechanism dependent on inhibition of the type I IFN
response. γ34.5 / is attenuated compared with γ34.5R after i.c.
inoculation of wt mice, demonstrating that HSV-2 ICP34.5 is
indeed a major neurovirulence factor. In contrast, γ34.5 /
replicates efﬁciently in the brain of IFNα/βR/ mice and is highly
lethal after i.c. inoculation. Thus, the capacity of ICP34.5 to
interdict the type I IFN response in vivo is critical to its role in
neurovirulence.
We found that HSV-2 ICP34.5 speciﬁcally overcomes IFNβ
priming in mouse and human ﬁbroblasts. γ34.5R replication was
reduced only 5-fold in IFNβ-pretreated MEFs and HFFs, whereas
γ34.5 / replication was attenuated more than 250-fold, indicat-
ing a critical role for ICP34.5 in counteracting signals transmitted
through the IFNα/βR. Type I IFN signaling primes a cell for
Fig. 2. γ34.5/ replication recovers to the level of γ34.5R in IFNα/βR/ MEFs. (A and B) Wt MEFs and (C and D) IFNα/βR/ MEFs were infected with (A,C) HSV-1 and (B,D)
HSV-2 strains at low MOI. Cultures were collected at the indicated time points and viral titers were determined by plaque assay. Data represent the geometric mean7SEM of
duplicate cultures from one representative experiment of two performed. n, p¼0.05–0.01; nn, p¼0.0099–0.001. Dotted line represents limit of detection in the plaque assay.
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translational shutoff in response to virus infection by activating
kinases to phosphorylate eIF2α. HSV-1 ICP34.5 opposes this
antiviral response by bringing PP1α and eIF2α into apposition,
leading to eIF2α dephosphorylation and uninterrupted translation.
The eIF2α and PP1α binding domains in HSV-1 ICP34.5 are highly
conserved in HSV-2, and we had previously found evidence of
functional conservation in that HSV-2 ICP34.5 protein levels
inversely correlate with eIF2α phosphorylation during HSV-2
infection (Wylie et al., 2009). In addition, expression of HSV-2
ICP34.5 by transient transfection was shown to prevent hyperpho-
sphorylation of eIF2α in cells infected with an HSV-1 γ34.5 mutant
(Tang et al., 2013). Here, we formally demonstrate that HSV-2
lacking ICP34.5 cannot oppose eIF2α phosphorylation. Cells
exposed to IFNβ upregulate kinases responsible for eIF2α phos-
phorylation, making them inhospitable to virus replication.
Restoration of γ34.5 / replication in IFNβ-treated, PKR-
deﬁcient MEFs indicates a principal role for PKR this antiviral
response to HSV-2 infection. Thus, HSV-2 ICP34.5 binding of eIF2α
and PP1αmay provide the mechanism underlying HSV-2 ICP34.5's
contribution to neurovirulence.
Our results that HSV-2 ICP34.5 disrupts the type I IFN response
by opposing post-receptor signaling inform our observation that
γ34.5 / replication recovered to the level of γ34.5R in MEFs
infected at low MOI. Under conditions of a low MOI infection, the
few infected cells in a monolayer or region of tissue are induced
to release type I IFNs, which then have a paracrine effect on
neighboring uninfected cells, signaling through the IFNα/βR to
prime for an antiviral response. The attenuation of HSV-2 γ34.5 /
compared with γ34.5R in wt MEFs infected at low MOI demon-
strates the effectiveness of this antiviral response in the absence of
ICP34.5 inhibition. IFNα/βR/ MEFs which are incapable of sensing
type I IFNs permit γ34.5/ to replicate unabated. These results
indicate ICP34.5 critically inﬂuences the replicative capacity of HSV-
2 early during infection when the virus faces a rapid innate immune
response. Interestingly, titers of HSV-2 γ34.5/ recovered to a
greater extent than HSV-1 Δγ34.5 in IFNα/βR/ MEFs (Fig. 2C and
D), even though HSV-1 ICP34.5 can inhibit both IFN induction and
responsiveness (Cheng et al., 2001a; Verpooten, Ma et al., 2009),
and replication of a γ34.5-deleted HSV-1 is completely restored in
PKR / MEFs (Cheng et al., 2001b). These observations suggest
another antiviral pathway independent of type I IFN signaling but
dependent on PKR contributes to suppression of HSV-1 lacking
ICP34.5. HSV-1 ICP34.5 binds Beclin-1 to help the virus oppose PKR-
dependent autophagy (Talloczy et al., 2002; Orvedahl et al., 2007),
and the pro-autophagic antiviral effects of the prion protein, PrP
(Korom et al., 2013). It will be interesting to determine whether
HSV-1 and HSV-2 ICP34.5 differ in their capacity to bind Beclin-1
and counteract PrP function, as the low amino acid sequence
conservation in the Beclin-1 binding domain would suggest. Alter-
natively, HSV-1 Δγ34.5 may remain partially attenuated in IFNα/
βR / MEFs because lack of ICP34.5 reduces expression the late
gene Us11 (Mulvey et al., 2003) which also helps preclude transla-
tional shutoff (Mulvey et al., 1999). HSV-2 Us11 expression may
therefore be independent of ICP34.5 or may not have the same
inﬂuence on virus ﬁtness.
Type I IFN plays an important role in limiting HSV-2 replication
in the mucosa and development of disease. From its peak at 2 d p.i.,
replication of γ34.5 / virus is rapidly controlled (Fig. 4A),
demonstrating the impact of the type I IFN response on a virus
that cannot counteract it. Rescue virus replication in the vaginal
mucosa of wt mice also diminishes after 2 d p.i.; however, high
titers persist in IFNα/βR / mice, as we have previously observed
(Murphy et al., 2003; Korom et al., 2008). Thus, even wild-type
HSV-2 cannot completely overcome the effects of type I IFN
in vivo. Two major factors contribute to genital inﬂammation:
damage due to lytic virus replication (Parr et al., 1994), and the
activities of immune cells that inﬁltrate the infected mucosa (Carr
and Tomanek, 2006; Duerst and Morrison, 2007). The control of
HSV-2 infection in the periphery exerted by type I IFN minimizes
signs of genital disease. Loss of this control in IFNα/βR / mice
causes rapidly worsening genital disease and permits virus dis-
semination from the periphery into the CNS (Fig. 5B). These
ﬁndings attest to the importance of the type I IFN response in
limiting virus infection and the signiﬁcance of HSV-2 ICP34.5 in
antagonizing it in vivo to promote viral replication and dissemina-
tion to the nervous system.
More than half of wt mice infected i.vag. with γ34.5 /
eventually succumbed to infection (Fig. 4A) despite the relatively
low viral titers detected in the spinal cords of cohorts 6 d p.i.
(Fig. 3C). This result caused us to question whether the type I IFN
response delayed but did not prevent γ34.5 / ampliﬁcation in
the nervous system. However, CNS tissues of wt mice infected
i.vag. with γ34.5/ that were moribund on day 13 p.i., did not
contain detectable virus (data not shown). From these experi-
ments it appears that γ34.5/ is able to enter the spinal cord by
or before day 6 p.i., but infection in the CNS is subsequently
controlled and morbidity results from some other pathologic
outcome of infection (Luker et al., 2003; Parr and Parr, 2003).
Intracranial infection bypasses the hurdles inherent in disse-
mination from a mucosal site to the CNS, and allows direct
assessment of neurovirulence. The low levels of γ34.5/ in the
brain of wt but not IFNα/βR / mice inoculated i.c. underscore the
critical role of ICP34.5 in surmounting the barrier posed by the
type I IFN response to HSV-2 replication in the brain. This property
is speciﬁc to ICP34.5 because another mutant, ΔTK , was attenu-
ated for replication in the brain of wt mice but failed to recover the
Fig. 5. γ34.5/ is highly lethal after i.vag. infection of IFNα/βR / mice. (A) Wt
mice and (B) IFNα/βR/ mice were infected i.vag. as in Fig. 3 and survival was
monitored daily. Data represent the day of death of a total of 10 mice per group
compiled from three independent experiments.
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capacity to replicate in the brain of IFNα/βR / mice. Increased
replication of γ34.5 / after i.c. inoculation of IFNα/βR / mice
also directly correlated with increased mortality. These results
indicate that the capacity of HSV-2 ICP34.5 to inﬂuence neuro-
virulence is directly related to its capacity to antagonize the type I
IFN response. Interestingly, HSV-1 γ34.5 deletion mutants are non-
lethal after corneal inoculation (Bolovan et al., 1994; Leib et al.,
2000) and are markedly reduced in virulence after intracranial
inoculation (Chou et al., 1990; Bolovan et al., 1994; Valyi-Nagy
et al., 1994; Leib et al., 2000). The mortality we observed with
γ34.5 / suggests HSV-2 may have components in addition to
ICP34.5 that contribute to its neurovirulence.
The inverted repeat regions of the HSV-2 genome where the two
copies of γ34.5 reside are transcriptionally complex, suggesting
mutations in γ34.5 could have pleotropic effects. The primary LAT is
encoded on the strand opposite γ34.5 and is the source of several
miRs: two miRs transcribed within LAT, miR-H4 and miR-H3, are
complementary to sequences in the 50 UTR and exon 1 of HSV-2
γ34.5, respectively (Tang et al., 2008, 2009), and both of these miRs
reduce ICP34.5 expression during productive infection in culture
(Tang et al., 2008, 2009). A third miR, miR-H24, is transcribed
within LAT and is complementary to a sequence in the ﬁrst exon of
HSV-2 γ34.5 (Jurak et al., 2010). A fourth miR, miR-H19, arises from
a sequence in the 50 UTR of γ34.5 and is complementary to miR-H4
in the 50 UTR of γ34.5 (Jurak et al., 2010). Importantly, the mutations
we made to generate γ34.5 / do not disrupt the pre-miRNAs or
mature sequences for miR-H4, miR-H19 or miR-H24, and alter only
a single base pairing in the miR-H3 pre-miRNA, although the impact
of miRs suppressing ICP34.5 expression is expected to be minimal
in a virus that does not synthesize ICP34.5. In addition, no evidence
of internal initiation or alternative splicing of the HSV-2 γ34.5
transcript has been found (Korom et al., 2014). Thus, the pheno-
types we observed in vitro and in vivo may be attributed to HSV-2
ICP34.5 because the speciﬁc mutations we introduced into both
copies of γ34.5 selectively prevented ICP34.5 expression. Complete
recovery of γ34.5/ replication in IFNα/βR/ MEFs and mice
further attests that the mutations used to create γ34.5 / do not
disrupt regulatory features of the locus, and emphasize the impor-
tance of ICP34.5 in controlling the type I IFN response to amplify
HSV-2 replication and pathogenesis.
Materials and methods
Cells and viruses
Vero cells were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 3% newborn calf serum
Fig. 6. γ34.5 / replicates in the brains of IFNα/βR/ mice and is highly lethal. (A) Wt mice and (B) IFNα/βR / mice were infected i.c. with 1103 pfu/mouse of the
indicated virus. Titer of virus in brain tissue was determined 24 h p.i. by plaque assay. Data represent the geometric meanþSEM of a total of 10 mice per group, compiled
from three independent experiments. (C) Wt mice and (D) IFNα/βR/ mice were infected i.c. with 1103 pfu/mouse of the indicated virus and survival was monitored daily.
Data represent the day of death of a total of 10 mice per group, compiled from two independent experiments. NS, no signiﬁcance; nnn, po0.0001. Dotted line represents limit
of detection in the plaque assay.
K.L. Davis et al. / Virology 468-470 (2014) 330–339336
and 3% bovine growth serum (BGS), 2 mM L-glutamine and
1 penicillin–streptomycin (P/S) (Invitrogen). Primary 129,
IFNα/βR / , and PKR/ MEFs were prepared from embryos at
15 to 18 d gestation and used through passage 4. MEFs were
cultured in DMEM supplemented with 10% BGS and 1 P/S. MEFs
(passage 1 to 4) were seeded into 24-well plates and allowed to
divide until conﬂuent (1105 to 2105 cells/well) or into 12-well
plates (3105 to 1106 cells/well when conﬂuent). Primary
human foreskin ﬁbroblasts (HFFs), derived from neonatal fore-
skins, were provided by David Sibley and were cultured in DMEM
supplemented with 10% fetal bovine serum, 1% L-glutamine, and
1% P/S. HFFs (passage 15–18) were seeded into 24-well plates and
allowed to divide until conﬂuent (1105 to 2105 cells/well).
All HSV-2 strains were in the wt strain 333 background (Duff
and Rapp, 1971). To generate a γ34.5 deletion virus, a BamHI
fragment of genomic DNA from HSV-2 strain 333 containing the
γ34.5 gene was cloned into the XhoI and EcoRI sites in pBS-KS(þ),
creating plasmid pBS-34.5gDNA (Korom et al., 2014). The SanDI
restriction site was utilized for insertion of a stop codon
at amino acid 13 by means of a short oligo-linker containing
a HpaI restriction site. Brieﬂy, oligos (Fwd 50-GTCCCCGTTAACGC-
CGCCGGG-30 and Rev 50-GACCCGGCGGCGTTAACGGG-30) were
suspended in STE buffer (10 mM Tris pH 8.0, 50 mM NaCl, 1 mM
EDTA) at 100 mM concentration. The two strands were mixed in
equimolar amounts, heated to 95 1C for 5 min and allowed to
gradually cool. The resulting double-stranded DNA fragment was
added at 10 mM concentration to a ligation reaction also containing
pBS-34.5 gDNA that had been digested with SanDI. The resulting
plasmid, pBS-34.5-HpaI, was veriﬁed by restriction digest and
sequencing. Two PCR fragments were generated from the pBS-
34.5-HpaI plasmid to introduce an M35A mutation in the γ34.5
gene and add a KpnI restriction site. The ﬁrst amplicon was
generated using primers Fwd 50-CTTAAGAGGGCCCGCAACAC-30
and Rev-50-CGCGGTACCCGAGTCGTACGCAGGGACCGCTTGGGAGT-
CTGCGGTTGGGAGC-30. The resulting three nucleotide substitu-
tions caused an amino acid change from Met to Ala and added a
unique KpnI site. The second amplicon was generated using
primers Fwd 50GACTCGGGTACCGCGGTCGAGAGCGCGCCGGCCGCG-
TCCTCGCTC-30 and Rev 50- CCCGGGCTGCAGGAATTCATTAGCATAC-
TAGGAAGCCCAGG-30. The ﬁrst PCR amplicon was digested with
HpaI and KpnI, and the second amplicon was digested with KpnI
and AgeI. A three-way ligation was performed with the amplicons
and HpaI-AgeI digested pBS-34.5-HpaI. The resulting pBS-34.5 /
clones were screened by HpaI and KpnI digests and were veriﬁed
by sequencing.
The mutated γ34.5 sequence in pBS-34.5 / was incorporated
into strain 333 viral DNA by homologous recombination after co-
transfection using Amaxa Nucleofector and Kit V (Lonza). Isolated
plaques were screened by PCR for replacement of both copies of
γ34.5 and plaque-puriﬁed to homogeneity to create virus γ34.5 /
 . Restriction digests and sequencing veriﬁed the presence and
location of the mutations. The γ34.5 rescue virus was isolated by
co-transfection of full-length γ34.5/ viral DNA with a linearized
plasmid containing the wild-type γ34.5 sequence, followed by PCR
screening of individual plaque isolates and plaque puriﬁcation to
homogeneity. Sequencing veriﬁed the replacement of both copies
of γ34.5 in this virus, γ34.5R.
The γ34.5-null mutant of HSV-1 strain 17, Δγ34.5, was
obtained from David Leib. Δγ34.5 contains a stop linker which
causes truncation of ICP34.5 after amino acid 30 (Bolovan et al.,
1994). Its marker rescue virus,Δγ34.5R, was isolated as previously
described (Korom et al., 2013). HSV-2 ΔTK is a TK-deﬁcient
mutant containing a 180 bp KpnI–KpnI deletion in the UL23 gene
that eliminates TK activity (McDermott et al., 1984). Viruses were
propagated on Vero cells and titers were determined by standard
plaque assay (Knipe and Spang, 1982).
Western blot analyses
Vero cells were mock-infected or infected at MOI of 5. Cell
monolayers were collected at 12 h p.i., lysed in 200 μl of lysis
buffer, and stored at 20 1C. Frozen lysates were thawed and
heated to 95 1C for 5 min, and 20 μl were loaded into a 14%
SDS-PAGE gel. After electrophoresis, proteins were transferred to
PVDF membranes which were blocked in Tris-buffered saline-
Tween 20 (TBST) containing 5% nonfat dry milk and incubated
with rabbit polyclonal antisera to HSV-2 ICP34.5 (Korom et al.,
2014), anti-eIF2α (Santa Cruz Biotechnology), or anti-phospho
eIF2α (Invitrogen). An anti-rabbit alkaline phosphatase-conju-
gated antibody (Promega) was used for detection. The primary
and secondary antibody incubations were carried out in TBST.
Bands were visualized using BCIP/NBT (Promega) according to the
manufacturers' instructions.
In vitro infection and assessment of virus replication
Primary MEFs generated from 129 wt, IFNα/βR / and PKR /
mice were seeded into 24-well plates. Conﬂuent monolayers were
infected with HSV-1 and HSV-2 strains at high MOI (10 pfu/cell) or
low MOI (0.01 pfu/cell). At 1 h p.i. virus was removed and cells
were gently washed with phosphate-buffered saline (PBS). Growth
medium was added to each well for the remainder of the
incubation. Infected cultures were collected by scraping at speciﬁc
time points and stored at 80 1C until use. Immediately following
sonication of samples, viral titers were determined by standard
plaque assay.
In vitro IFNβ treatment and infection
Conﬂuent MEFs were incubated with medium containing 100
or 1000 International Units/ml (IU/ml) of mouse IFNβ (PBL Inter-
feron Source), or with medium only. After 24 h of IFNβ treatment,
cells were gently washed twice with PBS and infected at high MOI
(10 pfu/cell) with various viruses. At 1 h p.i. virus was removed,
cells were gently washed with PBS, and DMEM supplemented
with 10% BGS was added for the remainder of the incubation
period. The contents of the well were collected 24 h p.i. and frozen
at 80 1C. Virus titers were determined by standard plaque assay
on Vero cells. Pre-treatment of HFFs followed the same procedure
with the exceptions of recombinant human IFNβ (Prospec) and
culture medium.
Animal studies
129 wt mice and IFNα/βR/ mice (129 background) (Muller
et al., 1994) were handled in strict accordance with good animal
practice as deﬁned by Institutional and Public Health Service
guidelines, and with work approved by the Institutional Animal
Care and Use Committee. The animals were housed and bred in
the Saint Louis University School of Medicine Department of
Comparative Medicine. Mice were treated subcutaneously with
Depo-Provera (3 mg/mouse) at 5 weeks of age and again one day
before i.vag. infection at 6 weeks of age. Groups of anesthetized
mice were infected with 1104 pfu/mouse of various viruses as
previously described (Korom et al., 2008). The vaginas of mice
were swabbed on days 1 through 5 p.i. with calcium alginate-
tipped applicators. The swabs were placed in a vial containing 1 ml
of PBS and stored at 80 1C until use. On days 1 through 6 p.i.,
mice were weighed and scored for genital disease using the scale:
0 no disease, 1 mild erythema, 2 moderate erythema and inﬂam-
mation, 3 genital lesions. 6 d p.i., mice were euthanized and the
brain, brainstem and spinal cord were dissected and placed
into microfuge tubes containing 1 ml PBS and 1 mm glass beads.
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To assess neurovirulence, groups of anesthetized mice were
infected i.c in the right cortex with 1103 pfu/mouse using a
29-gauge needle and 0.33 ml syringe (Terumo). Brain tissue was
dissected at 24 h p.i. Tissues were disrupted using a Mini Bead-
beater 8 (Prospec). Virus titers in vaginal swabs and homogenized
tissues were determined by plaque assay. Survival following i.vag
and i.c infections was monitored for 21 d p.i. and mice were
sacriﬁced if moribund. In some cases CNS tissues were dissected
13 d p.i. for determination of virus titer.
Statistics
Statistical signiﬁcance of differences in viral titers was deter-
mined by unpaired t test, in disease scores by the Kruskal–Wallis
test, and in survival curves by the Kaplan–Meier test.
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